|
|
BGI Genomics
Products >> Natera and BGI Genomics Announce Commercial Launch of the BGI
Build Your Online Product Catalogs?
| Product Name: |
Natera and BGI Genomics Announce Commercial Launch of the BGI
|
| Supply Ability: |
|
| Related proudcts |
natera and bgi genom, |
| Specifications |
Natera and BGI Genomics Announce |
| Price Term: |
|
| Port of loading: |
|
| Minimum Order |
|
| Unit Price: |
|
|
In March 2019, Natera and BGI China Genomics entered into a partnership to commercialize Natera¡¯s Signatera test in China,1 and after two years of technology transfers and validation, the BGI/Natera Signatera Assay is now officially available in the country. The assay can help facilitate innovative trial design and enable biopharmaceutical researchers to make better informed and more timely decisions. Pharmaceutical co***nies can access this assay in China through the BGI-Natera partnership, which offers unique opportunities for co***nion diagnostic registration in both China and the U.S.
"BGI is committed to promoting precision medicine and cancer prevention with cutting-edge technologies. Signatera can ***ect recurrence earlier and help clinicians optimize treatment decisions, thus bringing greater survival benefits for patients. In partnership with Natera, we are pleased to introduce Signatera into China and provide this innovative technology that incorporates MGI sequencing platforms for clinical oncology and drug development in a reliable and affordable manner," said Shida Zhu, general manager of BGI Oncology. |
| Company: |
BGI Genomics
|
| Contact: |
Tommy Ru |
| Address: |
beijing |
| Postcode: |
|
| Tel: |
17722567742 |
| Fax: |
|
| E-mail: |
|
|
|
|
Home
